StockData
RadNet, Inc. logo

RadNet, Inc. (RDNT) stock analysis

RDNTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3041% above fair value
$78.08+0.14 (+0.18%)

Close on Nov 11, 2026Market cap $6.14BP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth2Performance2Health3Dividend0

Weak7 of 30 checks passed

RadNet passes 7 of the 30 checks behind our score; 11 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
2/6
Financial health
3/6
Dividend
0/6

What stands out

  • Revenue growing 10%+ a year

    Revenue grew 12.6% a year over the last three fiscal years.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 26.2% of total debt.

  • Growing faster than the industry

    Revenue grew 21.1% over the last twelve months; the Health Services median is 16.9%.

  • Return on equity above the industry

    RadNet's return on equity of -2.1% is above the Health Services median of -9.9%.

What to watch

  • Margin of safety under 20%

    The price is 41.1% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $78.08 is above our fair value estimate of $55.32.

  • Return on equity under 15%

    Return on equity was -2.1% over the last twelve months and averaged 3.1% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 2.8%, below the 10% that usually covers the cost of capital.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA above its 5-year median

    RadNet's EV/EBITDA of 27.9 is above its 5-year median of 17.4.

  • P/B above the industry

    RadNet's price-to-book of 5.48 is above the Health Services median of 3.40.

  • Trading above fair value

    The share price of $78.08 is above our fair value estimate of $55.32.

  • Margin of safety under 20%

    The price is 41.1% above fair value, so there is no margin of safety.

Growth2/6

  • Revenue growing 10%+ a year

    Revenue grew 12.6% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 21.1% over the last twelve months; the Health Services median is 16.9%.

  • Guidance lowered

    RadNet lowered its full-year 2026 Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI - Digital Health Segment outlook on May 11, 2026.

  • Gross margin trend

    This company does not report gross profit.

Past performance2/6

  • Return on equity under 15%

    Return on equity was -2.1% over the last twelve months and averaged 3.1% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 2.8%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    RadNet's return on equity of -2.1% is above the Health Services median of -9.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin below its 5-year average

    Net margin was -0.9% over the last twelve months, against a 5-year average of 0.4%.

  • Net margin above the industry

    RadNet's net margin of -0.9% is above the Health Services median of -10.3%.

Financial health3/6

  • High debt

    Debt is 118% of shareholders' equity, above the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 394% five years ago to 118%.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 26.2% of total debt.

  • Interest not well covered

    Operating income covers interest expense 1.0 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 1.49 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 1.97; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    RadNet has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$55.32

The share price is 41% above this estimate.

20%+ below
Near fair value
20%+ above
$78.08Price$55.32Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
EV/EBITDA22.6×17.4×27.9×$65.1858%
P/B4.1×4.9×3.4×$58.9817%
Earnings power10.7% cost of equity––$29.8625%
Fair value$55.32100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Health Services median 23.9

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$50.15M
Value traded per 1% price move
$26.38M

Downside

Medium risk

Typical loss in a bad month
18.0%
Volatility (annualized)
43%
Sharpe ratio, 1 year
-0.18
Beta to the S&P 500 (5Y)
1.16

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

–

Operating margin

3.0%−0.3 pts over 5 years

Net margin

-0.9%+0.5 pts over 5 years

See a number that looks wrong?